Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 5, 1999, Pages 1497-1502

  Almawi, Wassim Y ^a,e   Tamim, Hala ^b   Azar, Sami T ^c,d  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF BALAMAND   (Lebanon)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d Chronic Care Center Hazmieh   (Lebanon)

^e SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ADHESION MOLECULE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL DAMAGE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; HELPER CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0033330911     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.5.5699     Document Type: Review

References (104)

1. The pathogenesis of insulin-dependent diabetes mellitus
2. Autoimmunity and genetics contribute to the risk of insulin-dependent diabetes mellitus in families: Islet cell antibodies and HLA DQ heterodimers
3. Protection against diabetes by MHC heterozygosity and reversal by cyclophosphamide
4. The immunogenetics of autoimmune diabetes and autoimmune thyroid disease
5. Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type I (insulin dependent) diabetes mellitus
6. Association of altered T cell immunity with insulin-dependent diabetes mellitus (IDDM). More than a cause and effect
7. Role of life events and difficulties in the onset of diabetes mellitus
8. Breast-feeding seems to play a marginal role in the prevention of IDDM
9. Increased serum levels of IgA antibodies to hsp 70 protein in patients with diabetes mellitus; their relationship with vascular complications
10. Autoantibodies in IDDM primarily recognize the 65,000-Mr rather than the 67,000-Mr isoform of glutamic acid decarboxylase
11. Characterization of T lymphocytes infiltrating human pancreas allograft affected by iselitis and recurrent diabetes
12. Immune regulation in type 1 diabetes
13. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients
14. Differential expression of ICAM-1 and LFA-1 vs. L-selection and VCAM-1 in auto-immune insulitis of NOD mice and association with both Th1 and Th2-type infiltrates
15. Monokine antagonism is reduced in patients with IDDM
16. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM
17. Cytokine gene expression in the BB rat pancreas: Natural course and impact of bacterial vaccines
18. Induction of type I diabetes by interferon-γ in transgenic mice
19. β-Cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice
20. Cellular and molecular mechanisms for the initiation and progression of β cell destruction resulting from the collaboration between macrophages and T cells
21. Both Th1 and Th2 cytokine mRNAs are expressed in the NOD mouse pancreas in vivo
22. Experimental models of type I diabetes
23. Involvement of interleukin-1 and interleukin-1 antagonism in pancreatic β-cell destruction in insulin-dependent diabetes mellitus
24. Interleukin 4 reverses T cell unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
25. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse
26. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomenon in NOD mice
27. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice
28. Pancreatic islet cell production of murine interleukin-10 does not inhibit immune-mediated tissue destruction
29. Insulin-dependent diabetes in the NOD mouse model. II. β-Cell destruction in autoimmune diabetes is a Th2- and not a Th1-mediated event
30. Cytokine- and co-stimulation-mediated therapy of IDDM
31. T-cell regulation in murine and human autoimmune diabetes: The role of Th1 and Th2 cells
32. Experimental immuno-prevention of type I diabetes mellitus
33. CD8 enhances formation of a stable T-cell receptor/MHC class I molecule complexes
34. CD4 augments the response of a T cell to agonist but not to antagonist ligands
35. The regulation and function of p21(ras) during T-cell activation and growth
36. T cell antigen receptor signal transduction pathways
37. + T cells
38. Duration of TCR stimulation determines co-stimulatory requirements of T cells
39. Synergistic interactions of IL-1 and IL-6 in T cell activation
40. Role of interleukin 1 in the activation of T lymphocytes
41. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD5
42. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
43. Regulation of lymphokine mRNA stability by a surface-mediated T cell activation pathway
44. CD28-mediated signaling costimulates murine T cells and prevents induction of energy in T cell clones
45. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response
46. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
47. Costimulation and autoimmunity
48. Immunomodulation of pancreatic islet allografts in mice with CTLA-4Ig secreting muscle cells
49. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
50. Th1 and Th2 cells. Different patterns of lymphokine secretion lead to different functional properties
51. Biology of human Th1 and Th2 cells
52. Single IL-2 secreting precursor CD4 T cell can develop into either Th1 of Th2 cytokine secretion phenotype
53. IL-4 directs the development of Th2-like helper functions
54. Reciprocal regulatory effect of IFN-γ and IL-4 on the in vitro development of human Th1 and Th2 clones
55. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype
56. Differential effect of IL-10 on dentritic cell-induced T cell proliferation and IFN-γ production
57. Role of antigen-presenting cells in the polarized development of helper T cell subsets: Evidence for differential cytokine production by Th0 cells in response to antigen presentation B cells and macrophages
58. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with interleukin (IL)-12 antagonist IL-12 (p40) 2
59. Natural killer cell stimulatory factor (interleukin 12) induces T helper type (T(H)1)-specific immune responses and inhibits the development of IL-4 producing T(H) cells
60. + T cells through IL-12 produced by Listeria induced macrophages
61. IL-4 dictates T-cell differentiation
62. Th1 and Th2 subsets: Paradigms lost?
63. The APC1 concept of type I diabetes
64. Functional diversity of helper T lymphocytes
65. Complexities in the treatment of autoimmune disease
66. T helper cell subsets in insulin-dependent diabetes
67. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes
68. + Th1 cells induce diabetes in NOD/SCID mice
69. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens
70. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse
71. Insulin and the prevention of insulin-dependent diabetes mellitus
72. Insulin therapy of prediabetes suppresses Th1 associated gene expression in BB rat pancreas
73. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens
74. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines
75. Suppression on insulitis in nonobese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin E
76. Primary non-function of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10
77. + Th1 and Th2 cells derived from the spleens of diabetic NOD mice
78. IL- 10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity
79. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice
80. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ
81. Interferon expression in the pancreas of patients with type I diabetes
82. Decreased IL-4 production in new-onset type I insulin-dependent diabetes mellitus
83. Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th1-type cytokines characterize the effector phase
84. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice
85. Genes encoding tumor necrosis factor β and granzyme A are expressed during development of autoimmune diabetes
86. Determinant spreading and the dynamics of the autoimmune T cell repertoire
87. Human tumor necrosis factor potentiates human interleukin-1 mediated rat pancreatic beta cell cytotoxicity
88. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice
89. Cyclophosphamide treatment of female nonobese diabetic mice cause enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not interleukin-4
90. Tissue-specific expression of interleukin-4 induces extracellular matrix accumulation and extravasation of B cells
91. The paradoxical effect of interleukin 10 in the immunoregulation of autoimmune diabetes
92. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes
93. Transgenic expression of IL-10 in pancreatic islet β cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice
94. IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection
95. Interleukin-10, a novel B cell stimulatory factor. Unresponsiveness of x chromosome-linked immunodeficiency B cells
96. Interkeulin-10 is a potent growth and differentiation factor for activated human B lymphocytes
97. IL-10: A novel cytotoxic T cell differentiation factor
98. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing IL-10 in the islets of Langerhans
99. Interleukin-10 drives human monocytes to CD16 positive macrophages
100. Interleukin 4 amplifies monocyte chemotactic protein and interleukin 6 production by endothelial cells
101. β Cell apoptosis in T cell mediated autoimmune diabetes
102. Regulation of cytokine production during development of autoimmune diabetes induced with low doses of streptozotocin
103. Genetic absence of gamma interferon delays but does not prevent diabetes in NOD mice
104. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation